An immunogenic composition for use in a method of inducing an immune response in an individual, the composition comprising: a) a hepatitis C virus E1/E2 heterodimeric polypeptide of a first HCV genotype, wherein the first HCV genotype is genotype 1, wherein the E1 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO: 1-27 of FIG. 1A-1C, and wherein the E2 polypeptide comprises an amino acid sequence having at least 80% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 1-27 of FIG. 1A-1C; b) an HCV E1 polypeptide, E2 polypeptide or E1/E2 heterodimeric polypeptide of a second HCV genotype, wherein the second HCV genotype is genotype 2, wherein the E1 polypeptide comprises an amino acid sequence having at least 70% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO: 41-53 of FIG. 9A-9C, and wherein the E2 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 41-53 of FIG. 9A-9C; c) an HCV E1 polypeptide, E2 polypeptide or E1/E2 heterodimeric polypeptide of a third HCV genotype, wherein the third HCV genotype is genotype 3, wherein the E1 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO:28-31 of FIG. 2A-2B, and wherein the E2 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 28-37 of FIG. 2A-2B; and d) a pharmaceutically acceptable excipient, wherein the composition does not include an HCV E1/E2 polypeptide, and E1 polypeptide, or an E2 polypeptide of any other genotype other than HCV genotype 1, HCV genotype 2 and HCV genotype 3; and wherein the E1 polypeptide has a length of from about 150 amino acids to about 193 amino acids, and wherein the E2 polypeptide has a length of from about 200 amino acids to about 365 amino acids; wherein the immune response: i) induces neutralizing antibody to HCV genotypes 1, 2, 3, 4, 5 and 6; or ii) induces a cytotoxic T lymphocyte response to HCV genotypes 1, 2, 3, 4, 5 and 6. a) a hepatitis C virus E1/E2 heterodimeric polypeptide of a first HCV genotype, wherein the first HCV genotype is genotype 1, wherein the E1 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO: 1-27 of FIG. 1A-1C, and wherein the E2 polypeptide comprises an amino acid sequence having at least 80% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 1-27 of FIG. 1A-1C; b) an HCV E1 polypeptide, E2 polypeptide or E1/E2 heterodimeric polypeptide of a second HCV genotype, wherein the second HCV genotype is genotype 2, wherein the E1 polypeptide comprises an amino acid sequence having at least 70% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO: 41-53 of FIG. 9A-9C, and wherein the E2 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 41-53 of FIG. 9A-9C; c) an HCV E1 polypeptide, E2 polypeptide or E1/E2 heterodimeric polypeptide of a third HCV genotype, wherein the third HCV genotype is genotype 3, wherein the E1 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E1 amino acid sequences depicted in SEQ ID NO:28-31 of FIG. 2A-2B, and wherein the E2 polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to any one of the E2 amino acid sequences depicted in SEQ ID NO: 28-37 of FIG. 2A-2B; and d) a pharmaceutically acceptable excipient, i) induces neutralizing antibody to HCV genotypes 1, 2, 3, 4, 5 and 6; or ii) induces a cytotoxic T lymphocyte response to HCV genotypes 1, 2, 3, 4, 5 and 6.